The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience

被引：1
|
作者：
Foster, Jared C. [1 ,3 ]
Korn, Edward L. [1 ]
Freidlin, Boris [1 ]
Moscow, Jeffrey A. [2 ]
机构：
[1] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA
[2] NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD USA
[3] NCI, Biometr Res Program, Div Canc Treatment & Diag, 9609 Med Ctr Dr,Room 5W638, Rockville, MD 20892 USA
来源：
JNCI CANCER SPECTRUM | 2023年 / 7卷 / 06期
关键词：
D O I：
10.1093/jncics/pkad102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute
    Zeidner, Joshua F.
    Karp, Judith E.
    Blackford, Amanda L.
    Foster, Matthew C.
    Dees, E. Claire
    Smith, Gary
    Ivy, S. Percy
    Harris, Pamela
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03):
  • [2] Analysis of esophagogastric cancer patients enrolled in National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials
    Bando, Hideaki
    Rubinstein, Larry
    Harris, Pamela Jo
    Yoshino, Takayuki
    Doi, Toshihiko
    Ohtsu, Atsushi
    Welch, Jack
    Takebe, Naoko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
    Lynce, Filipa
    Blackburn, Matthew J.
    Cai, Ling
    Wang, Heping
    Rubinstein, Larry
    Harris, Pamela
    Isaacs, Claudine
    Pohlmann, Paula R.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 35 - 41
  • [4] Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
    Filipa Lynce
    Matthew J. Blackburn
    Ling Cai
    Heping Wang
    Larry Rubinstein
    Pamela Harris
    Claudine Isaacs
    Paula R. Pohlmann
    Breast Cancer Research and Treatment, 2018, 168 : 35 - 41
  • [5] Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials
    Bando, Hideaki
    Rubinstein, Larry
    Harris, Pamela
    Yoshino, Takayuki
    Doi, Toshihiko
    Ohtsu, Atsushi
    Welch, John
    Takebe, Naoko
    GASTRIC CANCER, 2017, 20 (03) : 481 - 488
  • [6] Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials
    Hideaki Bando
    Larry Rubinstein
    Pamela Harris
    Takayuki Yoshino
    Toshihiko Doi
    Atsushi Ohtsu
    John Welch
    Naoko Takebe
    Gastric Cancer, 2017, 20 : 481 - 488
  • [7] Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
    Chihara, Dai
    Huang, Erich P.
    Finnigan, Shanda R.
    Cordes, Lisa M.
    Skorupan, Nebojsa
    Fukuda, Yoko
    Rubinstein, Larry, V
    Ivy, S. Percy
    Doroshow, James H.
    Nastoupil, Loretta J.
    Flowers, Christopher R.
    Takebe, Naoko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17) : 1949 - +
  • [8] The Effect on Drug Development of the National Cancer Institute's Cancer Therapy Evaluation Program
    Zwiebel, James
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 157 - 159
  • [9] Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health
    Chihara, Dai
    Huang, Erich P.
    Finnigan, Shanda R.
    Cordes, Lisa M.
    Skorupan, Nebojsa
    Fukuda, Yoko Korenaga
    Rubinstein, Larry V.
    Takebe, Naoko
    BLOOD, 2020, 136
  • [10] THE CANCER-THERAPY EVALUATION PROGRAM OF THE NATIONAL-CANCER-INSTITUTE
    MUGGIA, FM
    CARTER, SK
    MACDONALD, JS
    SEMINARS IN ONCOLOGY, 1981, 8 (04) : 394 - 402
12345